Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well

Nov 25 2016

• By Emily Hayes

Related Content

Sanofi Withdraws Zimulti NDA For Weight Loss

Jun 29 2007

Dravet Syndrome Indication Will Set GW Pharma Apart On US Epilepsy Market

Sep 27 2016

Death knell sounds for CB1 antagonists

Nov 06 2008

Cannabis Derivative Sativex 'Shows Promise In US Patients' Despite Further Phase III Failure

Oct 29 2015

GW Succeeding With Cannabinoid Drug This Time Around

Mar 14 2016

Related Companies

GW Pharmaceuticals plc

AbbVie Inc.

Viatris Inc.

INSYS Therapeutics, Inc.

Bayer AG

Novartis AG

Otsuka Holdings Co., Ltd.

Sanofi

Allergan plc

INSYS Therapeutics, Inc.

Sanofi

Bristol Myers Squibb Company

Abide Therapeutics Inc.

Additional Topics

Market Intelligence Strategy Research & Development Commercial BioPharmaceutical Market Snapshot

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window